Free Trial
NASDAQ:RVPH

Reviva Pharmaceuticals Q2 2024 Earnings Report

Reviva Pharmaceuticals logo
$0.82 +0.00 (+0.27%)
As of 05/9/2025 04:00 PM Eastern

Reviva Pharmaceuticals EPS Results

Actual EPS
-$0.26
Consensus EPS
-$0.28
Beat/Miss
Beat by +$0.02
One Year Ago EPS
N/A

Reviva Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Reviva Pharmaceuticals Announcement Details

Quarter
Q2 2024
Time
Before Market Opens
Conference Call Date
Wednesday, August 14, 2024
Conference Call Time
2:00AM ET

Upcoming Earnings

Reviva Pharmaceuticals' Q1 2025 earnings is scheduled for Tuesday, May 13, 2025

Reviva Pharmaceuticals Earnings Headlines

Reviva Pharmaceuticals (RVPH) Projected to Post Earnings on Tuesday
Market Panic: Trump Just Dropped a Bomb on Your Stocks
tock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tariffs just lit the fuse. Millions of investors are blindsided as stocks plunge… but this is only Phase 1. If you're still holding the wrong assets, you could lose 30% or more in the coming weeks.
RVPH: M&A Deals Highlight Brilaroxazine Value
See More Reviva Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Reviva Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Reviva Pharmaceuticals and other key companies, straight to your email.

About Reviva Pharmaceuticals

Reviva Pharmaceuticals (NASDAQ:RVPH), a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis. It is also developing RP1208 for the treatment of depression and obesity. Reviva Pharmaceuticals Holdings, Inc. was founded in 2018 and is headquartered in Cupertino, California.

View Reviva Pharmaceuticals Profile

More Earnings Resources from MarketBeat